User profiles for A. Menzies Gow

Andrew Menzies-Gow

Consultant Physician, Royal Brompton Hospital
Verified email at rbht.nhs.uk
Cited by 12735

Systematic literature review of systemic corticosteroid use for asthma management

ER Bleecker, AN Menzies-Gow, DB Price… - American journal of …, 2020 - atsjournals.org
Systemic corticosteroid use to manage uncontrolled asthma and its associated healthcare
burden may account for important health-related adverse effects. We conducted a systematic …

Anti-alarmins in asthma: targeting the airway epithelium with next-generation biologics

…, A Sverrild, CM Lloyd, AN Menzies-Gow… - European …, 2020 - Eur Respiratory Soc
Monoclonal antibody therapies have significantly improved treatment outcomes for patients
with severe asthma; however, a significant disease burden remains. Available biologic …

[HTML][HTML] The biology of eosinophils and their role in asthma

CN McBrien, A Menzies-Gow - Frontiers in medicine, 2017 - frontiersin.org
This review will describe the structure and function of the eosinophil. The roles of several
relevant cell surface molecules and receptors will be discussed. We will also explore the …

Eosinophil's role remains uncertain as anti–interleukin-5 only partially depletes numbers in asthmatic airway

PT Flood-Page, AN Menzies-Gow, AB Kay… - American journal of …, 2003 - atsjournals.org
The role of eosinophils as effector cells in asthma pathogenesis has been questioned since
an anti–interleukin (IL)-5 monoclonal antibody (mepolizumab), which depleted blood and …

[HTML][HTML] Tezepelumab in adults and adolescents with severe, uncontrolled asthma

A Menzies-Gow, J Corren, A Bourdin… - … England Journal of …, 2021 - Mass Medical Soc
Background Tezepelumab is a human monoclonal antibody that blocks thymic stromal
lymphopoietin, an epithelial-cell–derived cytokine implicated in the pathogenesis of asthma. The …

[HTML][HTML] Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics

P Flood-Page, A Menzies-Gow… - The Journal of …, 2003 - Am Soc Clin Investig
Eosinophil-derived TGF-β has been implicated in remodeling events in asthma. We hypothesized
that reduction of bronchial mucosal eosinophils with anti–IL-5 would reduce markers …

[HTML][HTML] Characterization of severe asthma worldwide: data from the International Severe Asthma Registry

…, TN Tran, LG Heaney, RC Jones, AN Menzies-Gow… - Chest, 2020 - Elsevier
Background Clinical characteristics of the international population with severe asthma are
unknown. Intercountry comparisons are hindered by variable data collection within regional …

Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma

…, RM Niven, CE Brightling, AN Menzies-Gow… - Journal of Allergy and …, 2013 - Elsevier
BACKGROUND: Clinical outcomes are worse in current smokers and exsmokers with mild-to-moderate
asthma compared with never smokers, but little is known about the influence of …

Anti–IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic …

A Menzies-Gow, P Flood-Page, R Sehmi… - Journal of Allergy and …, 2003 - Elsevier
Background: Eosinophils develop from CD34 + progenitors under the influence of IL-5. Atopic
asthmatic individuals have increased numbers of mature eosinophils and eosinophil pro-…

Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British …

J Sweeney, CC Patterson, A Menzies-Gow, RM Niven… - Thorax, 2016 - thorax.bmj.com
Objective To determine the prevalence of systemic corticosteroid-induced morbidity in severe
asthma. Design Cross-sectional observational study. Setting The primary care Optimum …